[Interleukin 1 receptor antagonists prevent the induction of experimental insulin-dependent autoimmune diabetes].
During the induction of diabetes with multiple low-dose of streptozotocin (40-45 mg/kg body weigh for 5 consecutive days) starting from day 3, CBA mice were injected repeatedly (10 daily injections) with either rat IL-1 inhibitor (IL-1 INH) derived from glucocorticoid-treated macrophages, or with recombinant DNA produced human IL-1 receptor antagonist (rIL-1ra). Althow not showing identity with each other, both agents by neutralisation of the activity of endogenous IL-1 interfered with the induction of diabetes. While control streptozotocin-treated mice developed sustained hyperglicemia with the late onset, histologically characterized with insulitis and islet cell destruction, mice injected with rat IL-1 INH, either in a form of dialyzed crude macrophage supernatant or partialy enriched 50-100 kDa fraction, remained normoglycemic. In agreement with diabetic status, insulitis and islet cell destruction were not observed in IL-1 INH treated mice. Human IL-1ra had milder, althow also significant protective effect. Our results, thus, suggest that IL-1 mediated immunopathogenic and/or inflammatory processes which lead to insulin-dependent diabetes, may be modulated by specific in vivo blockade of IL-1 receptors.